

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI
- An opportunity for Trump: Position U.S. cancer science to lead the world